S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
NYSE:RCUS

Arcus Biosciences (RCUS) Stock Price, News & Analysis

$19.53
-0.14 (-0.71%)
(As of 02/23/2024 ET)
Today's Range
$18.80
$19.68
50-Day Range
$14.82
$19.74
52-Week Range
$12.95
$25.47
Volume
1.28 million shs
Average Volume
1.04 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.25

Arcus Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
111.2% Upside
$41.25 Price Target
Short Interest
Bearish
22.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Arcus Biosciences in the last 14 days
Based on 18 Articles This Week
Insider Trading
Acquiring Shares
$320 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.03) to ($2.99) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

357th out of 936 stocks

Pharmaceutical Preparations Industry

163rd out of 422 stocks


RCUS stock logo

About Arcus Biosciences Stock (NYSE:RCUS)

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Stock Price History

RCUS Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
RCUS Mar 2024 30.000 call
RCUS Mar 2024 20.000 put
RCUS Mar 2024 10.000 call
RCUS Mar 2024 12.500 call
DTIL Mar 2024 2.500 put
Gilead deepens investment in Arcus and TIGIT drugs
Key Takeaways From Arcus Biosciences Analyst Ratings
Gilead Sciences Increases Stake In Arcus Biosciences To 33%
See More Headlines
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
2/25/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.25
High Stock Price Target
$70.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+111.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-267,000,000.00
Net Margins
-262.39%
Pretax Margin
-257.27%

Debt

Sales & Book Value

Annual Sales
$117 million
Book Value
$5.08 per share

Miscellaneous

Free Float
78,326,000
Market Cap
$1.77 billion
Optionable
Optionable
Beta
0.78
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Terry J. Rosen Ph.D. (Age 64)
    Co-Founder, Chairman & CEO
    Comp: $756.11k
  • Dr. Juan Carlos Jaen Ph.D. (Age 66)
    Co- Founder & President
    Comp: $931.14k
  • Mr. Robert C. Goeltz IIMr. Robert C. Goeltz II (Age 51)
    Principal Financial Officer & CFO
    Comp: $745.29k
  • Ms. Jennifer A. Jarrett M.B.A. (Age 53)
    Chief Operating Officer
    Comp: $925.29k
  • Dr. Dimitry S.A. Nuyten M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $700.34k
  • Dr. K. Christopher Garcia Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Alexander Azoy (Age 48)
    VP of Finance & Principal Accounting Officer
  • Dr. Stephen Young Ph.D. (Age 55)
    Senior Vice President of Technology & Quantitative Biology
  • Dr. Jonathan Yingling Ph.D. (Age 55)
    Chief Scientific Officer
  • Ms. Katherine Bock
    Vice President of Investor Relations & Corporate Strategy














RCUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RCUS shares.
View RCUS analyst ratings
or view top-rated stocks.

What is Arcus Biosciences' stock price target for 2024?

8 Wall Street analysts have issued 1 year price targets for Arcus Biosciences' stock. Their RCUS share price targets range from $23.00 to $70.00. On average, they predict the company's stock price to reach $41.25 in the next twelve months. This suggests a possible upside of 111.2% from the stock's current price.
View analysts price targets for RCUS
or view top-rated stocks among Wall Street analysts.

How have RCUS shares performed in 2024?

Arcus Biosciences' stock was trading at $19.10 at the beginning of 2024. Since then, RCUS stock has increased by 2.3% and is now trading at $19.53.
View the best growth stocks for 2024 here
.

When is Arcus Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RCUS earnings forecast
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings results on Wednesday, February, 21st. The company reported ($1.08) earnings per share for the quarter, beating analysts' consensus estimates of ($1.09) by $0.01. The firm had revenue of $31 million for the quarter, compared to the consensus estimate of $28.30 million. Arcus Biosciences had a negative net margin of 262.39% and a negative trailing twelve-month return on equity of 57.17%. The company's quarterly revenue was down 8.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.93) earnings per share.

What ETFs hold Arcus Biosciences' stock?
What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?
When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.25%), Octagon Capital Advisors LP (2.50%), Dimensional Fund Advisors LP (2.13%), Decheng Capital LLC (1.16%), Point72 Asset Management L.P. (1.03%) and Goldman Sachs Group Inc. (0.79%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends
.

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:RCUS) was last updated on 2/25/2024 by MarketBeat.com Staff